Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation

Simply Wall St.

Jan 09

Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602937770"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602937770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602937770?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-09 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602937770","market":"nz","top_or_hot":-1,"title":"Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation","media":"Simply Wall St.","content":"<div>\n<p>Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-ocs-valuation-after-privosegtors-fd\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-ocs-valuation-after-privosegtors-fd><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-ocs-valuation-after-privosegtors-fd\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCS","symbol_name":"Oculis","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-ocs-valuation-after-privosegtors-fd","article_id":"2602937770","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocs/oculis-holding/news/assessing-oculis-holding-ocs-valuation-after-privosegtors-fd","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602937770","pubTimestamp":1767968593,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials.\nSee our latest analysis for Oculis Holding.\nThe FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCS":"Oculis","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4007":"制药"},"translate_title":"Privosegtor获得FDA突破性疗法认定后评估Oculis Holding(OCS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"OCS":1.5},"content_text":"Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials. See our latest analysis for Oculis Holding. The FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very large 3 year total shareholder return suggest momentum has been building over time. If you are looking beyond a single ophthalmology name, this could be a helpful moment to scan other healthcare stocks that might fit a similar long term thesis. With Oculis sitting at $22.03, a value score of 2 and a large gap to a US$44.61 analyst target and intrinsic value estimates, investors now face the key question: is this a genuine mispricing or is future growth already baked in? AdvertisementPrice to Book of 7.8x: Is it justified? Oculis is trading on a P/B of 7.8x at a last close of $22.03, while its DCF based fair value estimate sits far higher at $187.08. This highlights how differently the SWS DCF model views the stock compared with the current market price. The P/B multiple compares the market value of the company to its net assets on the balance sheet and is often used for early stage or asset light biopharma names where earnings are not yet meaningful. For Oculis, the 7.8x P/B means investors are paying several times the accounting value of equity, even though the company is still generating a loss of US$104.098m on revenue below US$1m. Relative to the US Pharmaceuticals industry average P/B of 2.6x and a peer average of 6.6x, Oculis screens as clearly more expensive on this metric. This suggests the market is assigning a premium to its pipeline and future revenue potential rather than its current financials. At the same time, the SWS DCF model, which projects future cash flows and discounts them back to today, arrives at a fair value of $187.08. On this basis, the current share price appears to be trading at an 88.2% discount to that intrinsic estimate. See what the numbers say about this price — find out in our valuation breakdown. Result: Preferred multiple of P/B 7.8x (OVERVALUED) However, investors still need to weigh clinical and regulatory setbacks around OCS-01, OCS-02 and OCS-05, as well as ongoing heavy losses of US$104.098m on modest revenue. Find out about the key risks to this Oculis Holding narrative. Another View: DCF Points the Other Way While the 7.8x P/B suggests Oculis is expensive compared with the US Pharmaceuticals average of 2.6x and the peer average of 6.6x, our DCF model presents a contrasting perspective. With a fair value estimate of US$187.08 versus a US$22.03 share price, it indicates that Oculis appears heavily undervalued. For you as an investor, the key question is whether the DCF assumptions about future cash flows seem realistic enough to rely on. Look into how the SWS DCF model arrives at its fair value. OCS Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Oculis Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 877 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Oculis Holding Narrative If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view in minutes by starting with Do it your way. A great starting point for your Oculis Holding research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If Oculis has sparked your interest, do not stop here, there are plenty of other focused ideas you can check out in a few minutes.  Target income potential with these 11 dividend stocks with yields > 3% that combine yield with underlying business strength. Hunt for mispriced opportunities using these 877 undervalued stocks based on cash flows grounded in projected cash flows. Explore the next wave of automation by scanning these 28 AI penny stocks that are building real world AI products.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}